Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
NCT04296214 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2021-07-09
Summary
The investigators want to compare the global response rate of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after six months of treatment with 5-azacitidine on two different doses. First group of 50 mg/m2 for 10 days each 28 days versus 75 mg/m2 for 7 days on 28 days cycles.
Conditions
Interventions
- DRUG
-
5-azacitidine
Cycles of 28 days
Sponsors & Collaborators
-
Grupo Cooperativo de Hemopatías Malignas
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-01-01
- Primary Completion
- 2021-12-31
- Completion
- 2022-03-15
Countries
- Mexico
Study Locations
More Related Trials
-
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
NCT03483948 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT00915252 ·Status: COMPLETED ·Phase: PHASE2
-
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
NCT00923234 ·Status: TERMINATED ·Phase: PHASE1
-
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
NCT00102687 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
NCT03699384 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT01522976 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
NCT02147873 ·Status: TERMINATED ·Phase: PHASE2
-
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
NCT05209152 ·Status: TERMINATED ·Phase: PHASE1
-
Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia
NCT01235117 ·Status: COMPLETED ·Phase: PHASE2
-
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
NCT04842604 ·Status: COMPLETED ·Phase: PHASE3
-
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
NCT03047993 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
NCT01617226 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)
NCT01305499 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax
NCT06090786 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
NCT03614728 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
NCT01839240 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
NCT02319369 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
NCT02677922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy
NCT00387647 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
NCT03217838 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
NCT06196203 ·Status: RECRUITING ·Phase: PHASE2
-
Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes
NCT00379912 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
NCT04079296 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
NCT04266301 ·Status: TERMINATED ·Phase: PHASE3